Multiple sclerosis (Houndmills, Basingstoke, England) · 2021
Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schönfelder Kristina, Schuh Helene, Pfister Frederick, Krämer Julia, Eisenberger Ute, Skuljec Jelena, Hackert Jana, Ruck Tobias, Pfeuffer Steffen, Fleischer Michael, Gäckler Anja, Hagenacker Tim, Kribben Andreas, Meuth Sven G, Kleinschnitz Christoph, Pul Refik
Аннотация
BACKGROUND: Oral cladribine is an approved disease-modifying drug for the treatment of relapsing multiple sclerosis. In controlled clinical trials as well as in post marketing safety assessments, autoimmune conditions have not yet been reported as a specific side effect of cladribine.
OBJECTIVE AND RESULTS: Here, we report a case of anti-glomerular basement membrane antibody-mediated glomerulonephritis that occurred shortly after the fourth cladribine treatment cycle.
CONCLUSION: Neurologists should be attentive to the development of secondary autoimmunity in cladribine-treated patients.
OBJECTIVE AND RESULTS: Here, we report a case of anti-glomerular basement membrane antibody-mediated glomerulonephritis that occurred shortly after the fourth cladribine treatment cycle.
CONCLUSION: Neurologists should be attentive to the development of secondary autoimmunity in cladribine-treated patients.